Primary care follow-up of radical prostatectomy patients: A regional New Zealand experience
نویسندگان
چکیده
BACKGROUND Contemporary recommendations regarding the duration of follow-up after radical prostatectomy (RP) are highly heterogeneous. Protocol-based follow-up schemes have been implemented to facilitate the expeditious identification of patients with recurrence. The aim of this study is to assess the reliability and comfort of general practitioners (GPs) in follow-up of RP. METHODS Following institutional ethical approval, we performed a retrospective review in patients undergoing follow-up after RP between January 2004 and December 2010. Patient factors, disease variables, and follow-up prostate specific antigen (PSA) compliance was collected. "Noncompliant" follow-up care was defined as: patients that had not received a PSA for a 14 month period within 5 years of prostatectomy. Patient and disease-based risk factors for noncompliant follow-up were assessed. GPs were also surveyed in their follow-up practice of RP patients, to assess their familiarity in caring for these patients. RESULTS In total, 65 cases were identified that met the inclusion criteria. At 60 months of follow-up, 66% (43/65) of patients had a compliant follow-up regime. For patients with noncompliant follow-up at 60 months, median time of compliance did not differ significantly when assessing preoperative PSA, Gleason sum, extraprostatic extension, or surgical margin status. Of the GPs surveyed, 68% of GPs felt comfortable in follow-up of RP patients. Some 62% of GPs would expect the PSA to be < 0.1 and 25% of GPs would measure the PSA annually. CONCLUSION Our study identified that follow-up by GPs after RP is insufficient. Accordingly, there is a requirement for formal educational programs if primary care is to take a greater role in follow-up of these patients.
منابع مشابه
Implications of body mass index in Japanese patients with prostate cancer who had undergone radical prostatectomy.
OBJECTIVE To determine the association between obesity and prostate cancer in Japanese recurrence after primary treatment with radical prostatectomy. METHODS The subjects were 173 Japanese patients with prostate cancer who had been treated with radical prostatectomy at Chiba University Hospital between April 1997 and March 2007. Clinicopathological characteristics and biochemical recurrence o...
متن کاملTransrectal ultrasonography of the prostate.
Transrectal prostatic ultrasonography has been performed in 203 patients within the last year. This new diagnostic modality has proven reliable in quantitating decrease in volume of the primary tumor following therapy in 71% of patients with prostatic carcinoma (10 of 14 patients) in whom long-term follow-up is available. In 12 patients staged prior to radical prostatectomy, prostatic ultrasono...
متن کاملHifu as first line salvage therapy in prostate cancer local relapse after radical prostatectomy: 4-year follow-up outcomes.
BACKGROUND Prostate cancer (PCa) is the most commonly diagnosed malignancy in men and the second leading cause of cancer death in developed countries. Despite the primary treatments, 20-30% of patients experience a recurrence. The main objective of this study was to evaluate the clinical efficacy of salvage HIFU after radical prostatectomy in terms of biochemical free survival rate (BFSR) and P...
متن کاملPentafecta outcomes after robot-assisted laparoscopic radical prostatectomy: first 100 cases in Latinoamerican Hospital.
OBJECTIVE Radical prostatectomy (RP) is the standard treatment for cancer control in the long term. The rise of minimally invasive surgery and new technologies have yielded better results and enabled us to pursue more ambitious objectives. The main works still use the trifecta as classic presentation, but this does not cover all aspects of surgery. Pentafecta is a new and more comprehensive met...
متن کاملUpdated protocol and guest participant results from the ACCeRT clinical study
Introduction: Cancer cachexia is a condition often seen at diagnosis, throughout chemotherapeutic treatments and in end stage Non-Small Cell Lung Cancer patients. These patients often experience a shorter life-expectancy and deterioration in performance status and reduced quality of life. New multi˗targeted regimens are required to be tested in this population to address these issues. Material...
متن کامل